Terazosina [Inn-Spanish]

Terazosina [Inn-Spanish] Brand names, Terazosina [Inn-Spanish] Analogs

Terazosina [Inn-Spanish] Brand Names Mixture

No information avaliable

Terazosina [Inn-Spanish] Chemical_Formula

C₁₉H₂₅N₅O₄

Terazosina [Inn-Spanish] RX_link

http://www.rxlist.com/cgi/generic/teraz.htm

Terazosina [Inn-Spanish] fda sheet

Terazosina_[Inn-Spanish] FDA

Terazosina [Inn-Spanish] msds (material safety sheet)

Terazosina [Inn-Spanish] Synthesis Reference

M. Winn et al., U.S. Pat. 4,026,894 (1977)

Terazosina [Inn-Spanish] Molecular Weight

387.433 g/mol

Terazosina [Inn-Spanish] Melting Point

273 ^oC

Terazosina [Inn-Spanish] H₂O Solubility

29.7mg/mL

Terazosina [Inn-Spanish] State

Solid

Terazosina [Inn-Spanish] LogP

0.875

Terazosina [Inn-Spanish] Dosage Forms

Tablet

Terazosina [Inn-Spanish] Indication

For the treatment of symptomatic benign prostatic hyperplasia (BPH) and also for hypertension.

Terazosina [Inn-Spanish] Pharmacology

Terazosin, classified as a quinazoline, is similar to doxazosin and prazosin. As an alpha-adrenergic blocking agent, terazosin is used to treat hypertension and benign prostatic hypertrophy (BPH). Terazosin produces vasodilation and reduces peripheral resistance but in general has slight effect on cardiac output. Antihypertensive effect with chronic dosing is usually not accompanied by reflex tachycardia.

Terazosina [Inn-Spanish] Absorption

Essentially completely absorbed in man (90% bioavailability).

Terazosina [Inn-Spanish] side effects and Toxicity

LD₅₀=259.3mg/kg (i.v. in mice)

Terazosina [Inn-Spanish] Patient Information

Terazosina [Inn-Spanish] Organisms Affected

Humans and other mammals